Coagulation factor vii derivatives

A technology of derivatives and factors, applied in coagulation/fibrinolytic factors, microorganisms, angiosperms/flowering plants, etc., can solve problems such as increasing platelet aggregation, toxic side effects, and increasing serum half-life

Inactive Publication Date: 2004-08-18
NOVO NORDISK AS
View PDF55 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, prolonged use of heparin may also increase platelet aggregation and decrease platelet count, and is associated with the development of osteoporosis
2,3-dihydro-1,3-indanedione derivatives also have toxic side effects
Modification methods that allow partial PEGylation of the protein typically result in only about a 50% loss of the activity and greatly increase the serum half-life, allowing for a lower overall effective dose of the protein

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Coagulation factor vii derivatives
  • Coagulation factor vii derivatives

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0316] Construct coding FVII-(R396C), FVII-(Q250C), FVII-(P406C), FVII-(407C), FVII-(V158T / M298Q), FVII-(L305V / M306D / D309S), FVII-(K337A), FVII-(L305V), and FVII-(F374P) DNA:

[0317] Genes encoding FVII-(R396C), FVII-(Q250C), FVII-(P406C), FVII-(407C) (an added C-terminal Cys), FVII-(M298Q), FVII-(L305V / M306D / D309S), FVII-(K337A), FVII-(L305V), and FVII-(F374P) DNA constructs. Use the following primers:

[0318] For FVII-(R396C):

[0319] 5'-GCG CTC AGA GCC ATG CCC AGG AGT CCT CC-3' (SEQ ID NO: 3)

[0320] 5'-GGA GGA CTC CTG GGC ATG GCT CTG AGC GC-3' (SEQ ID NO: 4)

[0321] For FVII-(Q250C):

[0322] 5'-GCT CCG CCT GCA CTG TCC CGT GGT CCT CAC TGA CC-3' (SEQ ID NO: 5)

[0323] 5'-GGT CAG TGA GGA CCA CGG GAC AGT GCA GGC GGA GC-3' (SEQ ID NO: 6)

[0324] For FVII-(P406C):

[0325] 5'-GCG AGC CCC ATT TTG CrA GAC TAG AGG ATC TGG G-3' (SEQ ID NO: 7)

[0326] 5′-CCC AGA TCC TCT AGT CTA GCA AAA TGG GGC TCG C-3′ (sEQ ID NO: 8)

[0327] For FVII-(407C):

[0328] 5'-CCT GCG AG...

Embodiment 2

[0348] Example 2 Preparation of FVII-(R396C)

[0349] BHK cells were transfected for expression of the variant FVII-(R396C) essentially as described previously (Thim et al. (1988) Biochemistry 27, 7785-7793; Persson and Nielsen (1996) FEBS Lett. 385, 241-243). Factor VII polypeptides were purified as follows:

[0350] The conditioned medium was loaded onto a 25-ml QSepharose Fast Flow column (Pharmacia) to which 5 mM EDTA, 0.1% Triton X-100, and 10 mM Tris were added, the pH was adjusted to 8.0, and the conductivity was adjusted to 10-11 mS / cm by adding water. Biotech). From 10mM Tris, 50mM NaCl, 0.1% Triton X-100, pH 8.0 to 10mM Tris, 50mM NaCl, 25mM CaCl 2 , 0.1% Triton X-100, pH7.5 gradient to complete the protein elution. Fractions containing FVII-(R396C) were pooled and loaded onto a 25 ml column containing monoclonal antibody F1A2 (Novo Nordisk, Bagsvaerd Denmark) coupled to CNBr-activated Sepharose 4B (Pharmacia Biotech). The column was used to contain 10mM CaCl 2 ...

Embodiment 3

[0351] Example 3 Preparation of FVII-(M298Q)

[0352] BHK cells were transfected essentially as previously described (Thim et al. (1988) Biochemistry 27, 7785-7793; Persson and Nielsen (1996) FEBS Lett. 385, 241-243) to obtain the Express. Factor VII polypeptides were purified as follows:

[0353] The conditioned medium was loaded onto a 25-ml QSepharose Fast Flow column (Pharmacia) to which 5 mM EDTA, 0.1% Triton X-100, and 10 mM Tris were added, the pH was adjusted to 8.0, and the conductivity was adjusted to 10-11 mS / cm by adding water. Biotech). From 10mM Tris, 50mM NaCl, 0.1% Triton X-100, pH 8.0 to 10mM Tris, 1M NaCl, 5mM CaCl 2 , 0.1% Triton X-100, pH7.5 gradient to complete the protein elution. Combine the fractions containing FVII-(V158T / M298Q), add 10mM CaCl 2 , and loaded onto a 25 ml column containing monoclonal antibody F1A2 (NovoNordisk, Bagsvaaerd Denmark) coupled to CNBr-activated Sepharose 4B (Pharmacia Biotech). The column was used to contain 10mM CaCl ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to view more

Abstract

The present invention relates to novel human coagulation Factor VII polypeptides, Factor VII derivatives as well as polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.

Description

technical field [0001] The present invention relates to novel human blood coagulation factor VII derivatives, factor VII polypeptides, polynucleotide constructs encoding the polypeptides, vectors and host cells containing and expressing the polynucleotides, and pharmaceutical compositions containing factor VII derivatives , uses and treatments. Background technique [0002] Blood coagulation is a process consisting of complex interactions of various blood components (or factors) that ultimately produce a fibrin clot. Generally, the blood components involved in the so-called coagulation "cascade" are enzymatically inactive proteins (proenzymes or zymogens), which are converted into proteolytic enzymes by the action of activators (which are themselves activated coagulation factors). Coagulation factors that undergo this transition are generally referred to as "active factors" and are designated by adding the letter "a" to the coagulation factor name (eg, Factor VIIa). [000...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A01H4/00A01H5/00A01K67/00A01K67/027A61K38/22A61K38/36A61K38/43A61K38/48A61P7/02A61P7/04C07K14/745C07K14/81C07K19/00C12N5/00C12N5/10C12N15/09C12N15/15C12N15/63C12P21/02
CPCA61K38/4846A61P7/00A61P7/02A61P7/04C12N9/64
Inventor 埃贡·佩森
Owner NOVO NORDISK AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap